Share

FDA Clears Dexcom G7

Dexcom announced recently that the FDA has cleared its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all types of diabetes ages two years and older. Dexcom says it is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as...
Share

New Endocrine Society Clinical Practice Guideline Examines Better Ways to Manage Hypoglycemia in People with Diabetes

People with diabetes are benefiting from advances in medications and technologies to lower their risk of hypoglycemia, according to a Clinical Practice Guideline issued today by the Endocrine Society. The guideline, titled “Management of Individuals with Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline,” was published online and will appear in the March 2023 print...
Share

Hormone Discovery Could Predict Long Term Health of Men

Scientists from the University of Nottingham have discovered that the novel insulin-like peptide hormone INSL3 is consistent over long periods of time and is an important early biomarker for prediction of age-linked disease and published their findings in Frontiers in Endocrinology.  Researchers led by Richard Ivell, PhD, and Ravinder Anand-Ivell, PhD, FRSB, point out that...
Share

Repainting the Pituitary Landscape

Always mystifying and bit mysterious, the pituitary is the gland that sends out the orders to the other glands in the body, from regulating the adrenals and the thyroid to coordinating reproduction. However, thanks to a worldwide collaboration and a new database, this “master gland” is slowly but surely unlocking its secrets. The pituitary –...
Share

Topline Results Announced from Trial of Non-Pharmacological Treatment for Osteopenia

Bone Health Technologies (BHT) announced yesterday topline results of its pivotal trial of the Osteoboost Vibration Belt. The results found that using Osteoboost more than three times per week in each of four quarters provided a statistically significant reduction in the loss of vertebral bone strength among participants— with no reported device-related serious adverse events....